PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Biogen Inc. (BIIB)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US09062X1037

CUSIP

09062X103

Sector

Healthcare

IPO Date

Sep 16, 1991

Highlights

Market Cap

$21.95B

EPS (TTM)

$11.06

PE Ratio

13.62

PEG Ratio

6.24

Total Revenue (TTM)

$9.41B

Gross Profit (TTM)

$6.75B

EBITDA (TTM)

$2.90B

Year Range

$148.60 - $268.30

Target Price

$245.19

Short %

2.11%

Short Ratio

1.59

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
BIIB vs. GILD BIIB vs. LLY BIIB vs. CAH BIIB vs. SPY BIIB vs. TSM BIIB vs. BMY BIIB vs. VOO BIIB vs. UNH BIIB vs. VHT BIIB vs. MRK
Popular comparisons:
BIIB vs. GILD BIIB vs. LLY BIIB vs. CAH BIIB vs. SPY BIIB vs. TSM BIIB vs. BMY BIIB vs. VOO BIIB vs. UNH BIIB vs. VHT BIIB vs. MRK

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Biogen Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


2,000.00%4,000.00%6,000.00%8,000.00%JulyAugustSeptemberOctoberNovemberDecember
4,988.59%
1,438.48%
BIIB (Biogen Inc.)
Benchmark (^GSPC)

Returns By Period

Biogen Inc. had a return of -43.40% year-to-date (YTD) and -42.30% in the last 12 months. Over the past 10 years, Biogen Inc. had an annualized return of -7.22%, while the S&P 500 had an annualized return of 11.06%, indicating that Biogen Inc. did not perform as well as the benchmark.


BIIB

YTD

-43.40%

1M

-6.11%

6M

-34.61%

1Y

-42.30%

5Y*

-13.44%

10Y*

-7.22%

^GSPC (Benchmark)

YTD

24.34%

1M

0.23%

6M

8.53%

1Y

24.95%

5Y*

13.01%

10Y*

11.06%

Monthly Returns

The table below presents the monthly returns of BIIB, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-4.68%-12.03%-0.63%-0.38%4.71%3.06%-8.03%-3.96%-5.33%-10.24%-7.68%-43.40%
20235.05%-7.23%3.03%9.42%-2.57%-3.90%-5.15%-1.05%-3.87%-7.58%-1.46%10.55%-6.55%
2022-5.80%-6.63%-0.19%-1.50%-3.59%1.97%5.45%-9.15%36.66%6.16%7.67%-9.26%15.42%
202115.42%-3.44%2.52%-4.44%0.06%29.46%-5.64%3.73%-16.50%-5.76%-11.60%1.77%-2.02%
2020-9.40%14.71%2.59%-6.18%3.46%-12.88%2.67%4.71%-1.38%-11.14%-4.72%1.95%-17.48%
201910.92%-1.73%-27.94%-3.02%-4.34%6.65%1.69%-7.60%5.95%28.30%0.37%-1.03%-1.39%
20189.18%-16.91%-5.25%-0.08%7.44%-1.27%15.20%5.72%-0.05%-13.88%9.68%-9.83%-5.54%
2017-2.24%13.02%-5.26%-0.81%-8.64%9.52%6.72%9.31%-1.09%-0.47%3.37%-1.12%21.96%
2016-10.87%-5.00%0.35%5.64%5.36%-16.54%19.89%5.42%2.42%-10.49%4.96%-3.57%-7.43%
201514.64%5.25%3.09%-11.44%6.17%1.75%-21.08%-6.74%-1.85%-0.45%-1.26%6.79%-9.75%
201411.83%8.97%-10.22%-6.13%11.23%-1.27%6.05%2.59%-3.57%-2.94%-4.17%10.32%21.42%
20136.63%6.57%15.80%13.66%8.48%-9.39%1.36%-2.34%13.02%1.42%19.16%-3.92%91.00%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of BIIB is 4, meaning it’s performing worse than 96% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of BIIB is 44
Overall Rank
The Sharpe Ratio Rank of BIIB is 00
Sharpe Ratio Rank
The Sortino Ratio Rank of BIIB is 11
Sortino Ratio Rank
The Omega Ratio Rank of BIIB is 22
Omega Ratio Rank
The Calmar Ratio Rank of BIIB is 1313
Calmar Ratio Rank
The Martin Ratio Rank of BIIB is 44
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Biogen Inc. (BIIB) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for BIIB, currently valued at -1.61, compared to the broader market-4.00-2.000.002.00-1.612.10
The chart of Sortino ratio for BIIB, currently valued at -2.42, compared to the broader market-4.00-2.000.002.004.00-2.422.80
The chart of Omega ratio for BIIB, currently valued at 0.72, compared to the broader market0.501.001.502.000.721.39
The chart of Calmar ratio for BIIB, currently valued at -0.62, compared to the broader market0.002.004.006.00-0.623.09
The chart of Martin ratio for BIIB, currently valued at -1.71, compared to the broader market-5.000.005.0010.0015.0020.0025.00-1.7113.49
BIIB
^GSPC

The current Biogen Inc. Sharpe ratio is -1.61. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Biogen Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-2.00-1.000.001.002.003.00JulyAugustSeptemberOctoberNovemberDecember
-1.61
2.10
BIIB (Biogen Inc.)
Benchmark (^GSPC)

Dividends

Dividend History

Biogen Inc. provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.


0.00%1.00%2.00%3.00%4.00%5.00%6.00%7.00%$0.00$5.00$10.00$15.00$20.002017201820192020202120222023
Dividends
Dividend Yield
PeriodTTM2023202220212020201920182017
Dividend$0.00$0.00$0.00$0.00$0.00$0.00$0.00$22.23

Dividend yield

0.00%0.00%0.00%0.00%0.00%0.00%0.00%6.98%

Monthly Dividends

The table displays the monthly dividend distributions for Biogen Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2023$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2022$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2021$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2020$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2019$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2018$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2017$22.23$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$22.23

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-70.00%-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-66.59%
-2.62%
BIIB (Biogen Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Biogen Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Biogen Inc. was 90.24%, occurring on Apr 17, 1997. Recovery took 677 trading sessions.

The current Biogen Inc. drawdown is 66.59%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-90.24%May 14, 1996235Apr 17, 1997677Dec 22, 1999912
-90%Oct 17, 1991809Dec 28, 1994249Dec 21, 19951058
-66.59%Mar 23, 20152456Dec 20, 2024
-66.51%Mar 7, 200034Apr 24, 2000109Sep 27, 2000143
-62.59%Dec 19, 2000555Mar 11, 20031158Oct 15, 20071713

Volatility

Volatility Chart

The current Biogen Inc. volatility is 6.16%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%JulyAugustSeptemberOctoberNovemberDecember
6.16%
3.79%
BIIB (Biogen Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Biogen Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Valuation

The Valuation section provides an assessment of the market value of Biogen Inc. compared to its peers in the Drug Manufacturers - General industry.


PE Ratio
200.0400.0600.0800.01,000.013.6
The chart displays the price to earnings (P/E) ratio for BIIB in comparison to other companies of the Drug Manufacturers - General industry. Currently, BIIB has a PE value of 13.6. This PE value is considered to be low compared to the rest of the industry.
PEG Ratio
10.020.030.06.2
The chart displays the price to earnings to growth (PEG) ratio for BIIB in comparison to other companies of the Drug Manufacturers - General industry. Currently, BIIB has a PEG value of 6.2. This PEG ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Biogen Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab